Prognostic impact of anatomical extent of metastatic lymph node on gastric cancer: a propensity score matching study
- 1 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 23 (4), 773-782
- https://doi.org/10.1007/s12094-020-02468-7
Abstract
Purpose Current gastric cancer staging systems overlook the anatomic extent of metastatic lymph nodes (AEMLNs). This study aimed to analyze the prognostic impact of AEMLNs on gastric cancer (GC). Methods GC patients with metastatic lymph nodes (MLNs) undergoing curative surgery were retrospectively reviewed and assigned to perigastric (MLNs in station 1-6, PG) and extraperigastric group (7-12, with or without MLNs in PG area, EPG). Overall survival (OS), disease-free survival (DFS) and recurrence patterns were compared before and after 1:1 propensity score matching (PSM). Results 662 patients were enrolled, 341 (51.5%) and 321 (48.5%) of whom were in the PG and EPG, respectively. After PSM (n = 195), EPG showed poorer 5-year OS (43.4% vs 54.5%,p = 0.014) and DFS (65.0% vs 73.4%,p = 0.068) than PG. EPG had higher incidence of peritoneal recurrence (PR) than PG (19.4% vs 7.4%,p = 0.002). Multivariate analysis identified AEMLNs as prognostic factor for OS [HR = 1.409, 95% confidence interval (CI) 1.062-1.868), DFS (HR = 1.600, 95% CI 1.059-2.416) and PR (HR = 3.708, 95% CI 1.685-8.160). Conclusions The anatomic extent of metastatic lymph nodes has an independent prognostic role for GC. Including this element may improve the accuracy of current staging systems.Funding Information
- National Natural Science Foundation of China (81772579)
- Sanming Project of Medicine in Shenzhen (SZSM201911010)
This publication has 28 references indexed in Scilit:
- Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric AdenocarcinomaAnnals of Surgery, 2015
- Skip lymph node metastasis in gastric cancer: is it skipping or skipped?Gastric Cancer, 2015
- Clinical significance of skip lymph node metastasis in gastric cancer patientsEuropean Journal of Surgical Oncology, 2014
- Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the National Cancer Data BaseCancer, 2014
- Anatomic Extent of Metastatic Lymph Nodes: Still Important for Gastric Cancer PrognosisAnnals of Surgical Oncology, 2013
- Efficacy, Compliance and Reasons for Refusal of Postoperative Chemotherapy for Elderly Patients with Colorectal Cancer: A Retrospective Chart Review and Telephone Patient QuestionnairePLOS ONE, 2013
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric CancerJournal of Clinical Oncology, 2011
- The Will Rogers phenomenon: the effect of different diagnostic criteriaJournal of the Neurological Sciences, 2009
- Japanese Classification of Gastric Carcinoma – 2nd English Edition –Gastric Cancer, 1998